9.18
Inmune Bio Inc stock is traded at $9.18, with a volume of 310.15K.
It is down -1.29% in the last 24 hours and up +54.16% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$9.30
Open:
$9.3
24h Volume:
310.15K
Relative Volume:
0.90
Market Cap:
$203.54M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-5.497
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
-4.33%
1M Performance:
+54.16%
6M Performance:
+36.40%
1Y Performance:
-34.43%
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
INMB
Inmune Bio Inc
|
9.18 | 203.54M | 155.00K | -30.01M | -11.98M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.00 | 117.92B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
673.60 | 73.64B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
639.41 | 38.85B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
256.45 | 33.20B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
119.83 | 28.73B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
Oct-21-24 | Initiated | Alliance Global Partners | Buy |
Sep-27-24 | Initiated | Raymond James | Outperform |
Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
Jun-01-23 | Initiated | Robert W. Baird | Outperform |
May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
Jul-07-21 | Reiterated | Maxim Group | Buy |
Apr-21-21 | Initiated | B. Riley Securities | Buy |
Jan-22-21 | Reiterated | Maxim Group | Buy |
Sep-01-20 | Initiated | BTIG Research | Buy |
Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Maxim Group Analyst Says - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Brokerages - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Average Price Target from Brokerages - MarketBeat
INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Scotiabank Analyst Says - MarketBeat
Raymond James raises INmune Bio stock target to $23 - MSN
(INMB) Investment Report - Stock Traders Daily
INmune Bio price target raised to $23 from $22 at Scotiabank - Yahoo Finance
Raymond James raises INmune Bio stock target to $23 By Investing.com - Investing.com Nigeria
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer - The Manila Times
INmune Bio Inc. Reports Safe Phase 1 Results for INKmune™ in mCRPC, Opens Phase 2 Enrollment - Nasdaq
Major Clinical Milestone: INmune Bio's NK Cell Therapy Shows Perfect Safety Profile in Prostate Cancer Trial - StockTitan
Inmune Bio’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating - TipRanks
INmune Bio’s CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com Nigeria
Scotiabank raises INmune Bio stock target to $23 on new therapy - MSN
INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc. (NASDAQ: INMB) submitted an 8-K form to the Securities and Exchange Commission, revealing that the company had developed an Investor Presentati - Defense World
Market Insight: INmune Bio Inc (INMB)’s Notable Drop, Closing at 9.12 - The Dwinnex
Scotiabank raises INmune Bio stock target to $23 on new therapy By Investing.com - Investing.com South Africa
BLA Submission Planned for CORDStrom in RDEB - MD Magazine
Inmune Bio Secures License Agreement for CORDStrom Data - TipRanks
INmune Bio's CORDStrom shows promise in RDEB treatment - MSN
INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe -February 10, 2025 at 10:26 am EST - Marketscreener.com
Inmune Bio Completes Phase 2 Trial for CORDStrom - TipRanks
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - Markets Insider
INmune Bio's CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com South Africa
INmune Bio (INMB) to Submit FDA Biologics License Application Seeking Approval of CORDStrom - StreetInsider.com
Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Expands By 7.0% - MarketBeat
INmune Bio Inc (INMB) shows promising results - US Post News
Trading Day Review: INmune Bio Inc (INMB) Loses Momentum, Closing at 9.31 - The Dwinnex
Analyzing INmune Bio Inc (INMB) After Recent Trading Activity - Knox Daily
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 7.0% in January - Defense World
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - Insider Monkey
(INMB) Proactive Strategies - Stock Traders Daily
INmune Bio (NASDAQ:INMB) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
Rodman & Renshaw Begins Coverage on INmune Bio (NASDAQ:INMB) - MarketBeat
INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
BTIG maintains INmune Bio stock Buy rating and $21 target By Investing.com - Investing.com Australia
INmune Bio advances prostate cancer trial at VA Hospital By Investing.com - Investing.com South Africa
BTIG maintains INmune Bio stock Buy rating and $21 target - MSN
INmune Bio advances prostate cancer trial at VA Hospital - Investing.com
Rodman & Renshaw sets INmune Bio stock Buy rating, $23 target - Investing.com
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans - The Manila Times
Groundbreaking NK Cell Cancer Treatment Now Available to Veterans: Major Trial Expansion - StockTitan
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):